Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobo Mintzer

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
International Psychogeriatrics|August 20, 2025
Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working groupAndrew A Namasivayam, Corinne E Fischer, Victor Abler, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 29, 2023
Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 TrialKrista L Lanctôt, Luc Rivet, Shankar Tumati, et al.
International Psychogeriatrics|January 11, 2026
Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) studyKrushnaa Sankhe, Myuri Ruthirakuhan, Ana C Andreazza, et al.
Alzheimer'S Research & Therapy|November 18, 2025
Drug repurposing for Alzheimer's disease: a Delphi consensus and stakeholder consultationAnne Corbett, Janet Sultana, Kate Stych, et al.
Journal of Neurotrauma|January 30, 2021
Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical TrialOlga Brawman-Mintzer, X Charlene Tang, Marcel Bizien, et al.
International Psychogeriatrics|April 17, 2023
Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)Krista L Lanctôt, Clara Chen, Ethan Mah, et al.
Archives of Neurology|January 21, 2004
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman, Ronald C Petersen, Steven H Ferris, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 5, 2021
Diagnostic criteria for apathy in neurocognitive disordersDavid S Miller, Philippe Robert, Larry Ereshefsky, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|October 5, 2023
Life-Course Brain Health as a Determinant of Late-Life Mental Health: American Association for Geriatric Psychiatry Expert Panel RecommendationsHarris A Eyre, Lucy E Stirland, Dilip V Jeste, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humansTrygve E Bakken, J Cooper Roddey, Srdjan Djurovic, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
International Psychogeriatrics|August 20, 2025
Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working groupAndrew A Namasivayam, Corinne E Fischer, Victor Abler, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|June 29, 2023
Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 TrialKrista L Lanctôt, Luc Rivet, Shankar Tumati, et al.
International Psychogeriatrics|January 11, 2026
Peripheral biomarkers associated with apathy and predicting response to methylphenidate: Secondary analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET2) studyKrushnaa Sankhe, Myuri Ruthirakuhan, Ana C Andreazza, et al.
Alzheimer'S Research & Therapy|November 18, 2025
Drug repurposing for Alzheimer's disease: a Delphi consensus and stakeholder consultationAnne Corbett, Janet Sultana, Kate Stych, et al.
Journal of Neurotrauma|January 30, 2021
Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical TrialOlga Brawman-Mintzer, X Charlene Tang, Marcel Bizien, et al.
International Psychogeriatrics|April 17, 2023
Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)Krista L Lanctôt, Clara Chen, Ethan Mah, et al.
Archives of Neurology|January 21, 2004
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trialsMichael Grundman, Ronald C Petersen, Steven H Ferris, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 5, 2021
Diagnostic criteria for apathy in neurocognitive disordersDavid S Miller, Philippe Robert, Larry Ereshefsky, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|October 5, 2023
Life-Course Brain Health as a Determinant of Late-Life Mental Health: American Association for Geriatric Psychiatry Expert Panel RecommendationsHarris A Eyre, Lucy E Stirland, Dilip V Jeste, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humansTrygve E Bakken, J Cooper Roddey, Srdjan Djurovic, et al.
Pageof 7